Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468172 | 0.93 | PTPRB (0.61) | PTPRBPTPN11 | |
| SCHEMBL501040 | 0.93 | PTPRB (0.61) | PTPRBPTPN11 | |
| SCHEMBL29794262 | 0.93 | PTPRB (0.61) | PTPRBPTPN11 | |
| SCHEMBL29794256 | 0.84 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL468143 | 0.84 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL679649 | 0.84 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL16079950 | 0.83 | PTPRB (0.65) | PTPRBPTPN11 | |
| SCHEMBL684952 | 0.82 | PTPRB (0.65) | PTPRB | |
| SCHEMBL8769454 | 0.81 | PTPRB (0.64) | PTPRBPTPN11 | |
| SCHEMBL500493 | 0.81 | PTPRB (0.63) | PTPRBPTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106078-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | WARNER CHILCOTT COMPANY, LLC (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885PTPN11 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.